Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SFDMO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Epratuzumab-SN38
|
|||||
| Synonyms |
Epratuzumab SN38
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Leukemia [ICD11:2A60-2B33]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Epratuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Govitecan
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.06 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.19 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.34 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.38 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.41 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.46 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.46 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.50 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.51 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.73 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.81 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.83 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.84 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.16 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.16 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.66 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.72 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.77 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.84 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.21 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.29 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.45 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.88 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.52 nM | High CD22 expression (CD22+++; Median fluorescence=145.0) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.68 nM | Negative CD22 expression (CD22-; Median fluorescence=7.7) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.22 nM | Low CD22 expression (CD22+; Median fluorescence=22.9) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.50 nM | Low CD22 expression (CD22+; Median fluorescence=22.9) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.68 nM | Low CD22 expression (CD22+; Median fluorescence=22.9) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Adult B acute lymphoblastic leukemia | RS4;11 cells | CVCL_0093 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.10 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.25 nM | Low CD22 expression (CD22+; Median fluorescence=11.2) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.67 nM | Low CD22 expression (CD22+; Median fluorescence=16.0) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Childhood B acute lymphoblastic leukemia | 697 cells | CVCL_0079 | ||
| Experiment 34 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.70 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 35 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.92 nM | Moderate CD22 expression (CD22++; Median fluorescence=40.8) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 36 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.20 nM | Moderate CD22 expression (CD22++; Median fluorescence=45.9) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 37 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.65 nM | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
|
||||
| In Vitro Model | Burkitt lymphoma | MN-60 cells | CVCL_1421 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.